+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Europe Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4997208
  • Report
  • April 2022
  • Region: Europe
  • 82 Pages
  • Mordor Intelligence


  • Abbott Laboratories
  • bioMerieux SA
  • F Hoffmann-la Roche Ltd
  • Hologic Corporation
  • Myriad Genetics
  • Sysmex Corporation

The European molecular diagnostics market was valued at USD 2574.61 million in 2021, and it is expected to reach USD 10,747.66 million in 2027, registering a CAGR of 12.65% during the forecast period.

The COVID-19 outbreak is expected to positively impact the European molecular diagnostics market, as it involves the testing of various biological samples. This is expected to aid the diagnosis of infectious diseases, such as COVID-19, as testing remains a crucial step in controlling the COVID-19 pandemic. Molecule diagnostics technology, such as next-generation sequencing, PCR, microarrays, etc., is increasingly adopted in the region for testing for severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). For instance, in June 2021, Fujirebio Europe commercially launched its iAMP COVID-19 molecular assay and its partner, Atila Biosystems Inc. The iAMP COVID-19 test is intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nylon nasopharyngeal/ oropharyngeal swabs. iAMP COVID-19 is an isothermal assay based on new proprietary technologies.

Factors, such as the increasing burden of various bacterial and viral epidemics in this region, coupled with increasing demand for point-of-care diagnostics and recent advancements in pharmacogenomics, are expected to propel market growth over the forecast period.

According to the article “HIV/AIDS surveillance in Europe 2020 data,” published in November 2021, HIV infection continues to affect the wellbeing and health of millions of people in the WHO European Region. Over the last three decades, approximately 2.2 million people have been diagnosed with HIV in the WHO European Region which has an impact in the studied market. Moreover, in 2020, 104,765 people were newly diagnosed with HIV. Moreover, according to the facts and figures published in British Heart Foundation updated in October 2021, Heart and circulatory diseases cause more than 160,000 deaths each year in the United Kingdom and around 7.6 million people are living with a heart or circulatory disease in the United Kingdom. Thus, the heavy burden of chronic disease is anticipated to increase the adoption of molecular diagnostics in the region.

The market players in the region are focused on product and technological development, which is boosting the market revenue. For instance, in March 2021, Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, received Conformité Européenne (CE) Mark for its innovative TruBlood solution, a new paradigm in cancer detection, diagnosis, and management. Hence, due to the factors mentioned above, the market is anticipated to achieve high growth rates over the forecast period.

Key Market Trends

The Infectious Disease Segment is Expected to Hold the Major Market Share

The infectious disease segment is anticipated to hold one of the major market shares over the forecast period. The segment is driven by the huge burden of infectious disease in the European region. For instance, sexually transmitted infections (STIs) represent an important public health problem in the United Kingdom. According to Sexually transmitted infections and screening for chlamydia in England, 2020, 317,901 new STI diagnoses were made at sexual health services (SHSs) in England. Among these, the most commonly diagnosed STIs were chlamydia (161,672; 51% of all new STI diagnoses), first episode genital warts (27,473; 9%), gonorrhoea (57,084; 18%), and genital herpes (20,530; 6%). Therefore, a rise in the prevalence of such infectious disorders is expected to fuel the market growth during the forecast period.

Moreover, players in the region are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for the diagnosis and introducing new products to retain their market share.

For instance, in May 2021, Swiss pharmaceutical giant, Roche, entered into a definitive merger agreement with GenMark Diagnostics, under which Roche may acquire GenMark’s molecular tests designed to screen patient samples for multiple infections simultaneously. Hence, considering all the factors mentioned above, the market is expected to witness growth over the forecast period.

Competitive Landscape

The European molecular diagnostics market is competitive due to the presence of almost all global players in the molecular diagnostics market. Many of these global players have their headquarters in European countries, which increases the accessibility of molecular diagnostics tests throughout Europe.

Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technologies are some of the key players present in the European molecular diagnostics market. Many of the key players also have their research and development centers in Europe, which makes the availability of various products easier in the region.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Abbott Laboratories
  • bioMerieux SA
  • F Hoffmann-la Roche Ltd
  • Hologic Corporation
  • Myriad Genetics
  • Sysmex Corporation

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Point-of-care Diagnostics
4.2.2 Advancements in Pharmacogenomics and Other Technologies
4.2.3 Possibility of Outbreaks of Bacterial and Viral Epidemics
4.3 Market Restraints
4.3.1 Need for High-complexity Testing Centers
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Technology
5.1.1 In Situ Hybridization
5.1.2 Chips and Microarrays
5.1.3 Mass Spectrometry (MS)
5.1.4 Sequencing
5.1.5 PCR
5.1.6 Other Technologies
5.2 By Application
5.2.1 Infectious Diseases
5.2.2 Oncology
5.2.3 Pharmacogenomics
5.2.4 Microbiology
5.2.5 Genetic Disease Testing
5.2.6 Other Applciations
5.3 By Product
5.3.1 Instruments
5.3.2 Reagents
5.3.3 Other Products
5.4 By End User
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Other End Users
5.5 By Geography
5.5.1 Germany
5.5.2 United Kingdom
5.5.3 France
5.5.4 Italy
5.5.5 Spain
5.5.6 Rest of Europe
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Agilent Technologies
6.1.3 Becton, Dickinson and Company
6.1.4 Danaher Corporation
6.1.5 F Hoffmann-la Roche Ltd
6.1.6 Genomic Health Inc.
6.1.7 Hologic Corporation
6.1.8 Illumina Inc.
6.1.9 Myriad Genetics
6.1.10 Qiagen NV
6.1.11 Thermo Fisher Scientific
6.1.12 Sysmex Corporation
6.1.13 bioMerieux SA
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher Corporation
  • F Hoffmann-la Roche Ltd
  • Genomic Health Inc.
  • Hologic Corporation
  • Illumina Inc.
  • Myriad Genetics
  • Qiagen NV
  • Thermo Fisher Scientific
  • Sysmex Corporation
  • bioMerieux SA
Note: Product cover images may vary from those shown